Veraxa Biotech Reports In Vivo Proof-of-Concept for BiTAC-ADC
The company reported tumor regression at a single 3 mg/kg dose in a xenograft breast cancer model, with no body-weight decrease observed.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.